Literature DB >> 2860233

The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity.

D C Taylor, R Pownall, W Burke.   

Abstract

Intestinal absorption characteristics of eleven beta-adrenoceptor antagonists were measured by monitoring their disappearance from in-situ intestinal loops in the anaesthetized rat. All have basic pKa values of around 9.5 (with the exception of sotalol) but show a wide range of lipophilic character (octanol-water log P values from -0.79 to 3.65). The results show two types of absorption behaviour, indicating different mechanisms for 'hydrophilic' and 'lipophilic' beta-adrenoceptor antagonists. The four most hydrophilic molecules (sotalol, atenolol, nadolol and practolol) show virtually identical absorption rate constants. Absorption is slow and relative rates in jejunum (mean pH 6.5) and ileum (mean pH 7.3) are not consistent with pH-partition (jejunum greater than or equal to ileum). The more lipophilic members of the series (pindolol, timolol, metoprolol, oxprenolol, alprenolol and propranolol) are all absorbed much more rapidly. Absorption rate constant rises rapidly with log P and the expected pH effects are seen (ileum greater than jejunum). Acebutolol shows anomalously slow absorption for its log P value.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860233     DOI: 10.1111/j.2042-7158.1985.tb05064.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

Review 1.  Lipophilicity and its relationship with passive drug permeation.

Authors:  Xiangli Liu; Bernard Testa; Alfred Fahr
Journal:  Pharm Res       Date:  2010-10-30       Impact factor: 4.200

2.  Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion.

Authors:  N Takamatsu; L S Welage; N M Idkaidek; D Y Liu; P I Lee; Y Hayashi; J K Rhie; H Lennernäs; J L Barnett; V P Shah; L Lesko; G L Amidon
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

Review 3.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

4.  Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose.

Authors:  S Y A Cheung; T Rodgers; L Aarons; I Gueorguieva; G L Dickinson; S Murby; C Brown; B Collins; M Rowland
Journal:  Br J Pharmacol       Date:  2017-12-01       Impact factor: 8.739

5.  Drug delivery studies in Caco-2 monolayers. Synthesis, hydrolysis, and transport of O-cyclopropane carboxylic acid ester prodrugs of various beta-blocking agents.

Authors:  L Hovgaard; H Brøndsted; A Buur; H Bundgaard
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

6.  Development and evaluation of an in vitro vaginal model for assessment of drug's biopharmaceutical properties: curcumin.

Authors:  Katja Berginc; Nataša Skalko-Basnet; Purusotam Basnet; Albin Kristl
Journal:  AAPS PharmSciTech       Date:  2012-08-17       Impact factor: 3.246

7.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

8.  The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.

Authors:  S M Kuo; B R Whitby; P Artursson; J A Ziemniak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

Review 9.  Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?

Authors:  H Lennernäs
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

10.  Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: A solvatochromic analysis.

Authors:  Nemanja Trišović; Nataša Valentić; Gordana Ušćumlić
Journal:  Chem Cent J       Date:  2011-10-14       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.